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The development of radio-ligands with a high spe-
cific activity has greatly facilitated the study of hor-
monal receptor systems. These receptor studies
have given us insight into the actions of drugs al-
ready available and should be helpful in assessing
potential drugs, both for their desired and undesired
effects.
The kidney is the most physiologically important
end organ for some hormones (for example, al-
dosterone, antidiuretic hormone). In addition, some
hormones with multiple actions have unique actions
within the kidney (for example, parathyroid hor-
mone and phosphate excretion). The kidney may al-
so act as an end organ in a relatively subordinate
role compared with a hormone's action elsewhere
in the body (for example, glucocorticoids). Demon-
stration of a hormone receptor system within the
kidney, as elsewhere, does not, by itself, imply any
physiologic action of the ligand. Before allowing re-
ceptor studies to influence assessments of drugs, we
need to evaluate carefully the receptor for the ef-
fector systems and their physiologic importance.
By intentionally manipulating the hormone recep-
tor systems, we can seek the desired effects and
evaluate them. Problems arise in the kidney in dis-
cerning unintentional manipulation of receptor sys-
tems, otherwise known as side effects. This prob-
lem arises because of the kidneys' remarkable capa-
bility to adapt to a functional impairment with a
minimal change in the internal environment [I]. The
kidneys' ability to adapt to functional impairment is
most easily demonstrated with progressive loss of
renal function, where many aspects of homeostasis
are achieved until late in the disease [1]. A similar
adaptation in function can be seen with drug-medi-
ated manipulation of a specific kidney function. For
instance, in healthy people, the administration of di-
uretics of any type is hard to discern except in the
early diuretic phase, for sodium and potassium bal-
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ance are achieved rapidly with a minimal observ-
able change in sodium or potassium homeostasis.
Evaluation of drugs by receptor studies may guide
in predicting likely undesired effects.
In this paper, two topics will be discussed that, at
first, may seem quite distinct but for which there
does seem to be evidence for their interrelationship
in both renal and extrarenal sites. The first is drug
interaction with the aldosterone receptor, as an ex-
ample of a hormone receptor system in which the
kidney is the end organ of major physiologic impor-
tance. The second is the dopamine receptor in the
kidney, studies of which might provide some future
insight into possible problems with dopaminergic
drugs. The discussion of renal dopamine receptors
will include previously unreported studies on renal
dopamine binding.
Aldosterone
Action of aldosterone. The major action of al-
dosterone is on sodium and potassium transport
across epithelial tissues [2, 3]. In mammals, the
most biologically significant end organ affected by
aldosterone is the kidney. Aldosterone does exert
similar effects on sodium and potassium transport in
other secretory organs (for example, bowel, sali-
vary and sweat glands), but under normal circum-
stances these organs add little to the homeostatic
control of sodium and potassium. Aldosterone also
has an effect on hydrogen ion transport, which at
times may become quite significant [4]. In amphibi-
ans, however, the action of aldosterone on the blad-
der and the skin may contribute to control of so-
dium and potassium balance.
Received for publication May 29, 1980
0085—2538180/0018-0623 $02.60
© 1980 by the International Society of Nephrology
624 Adam
Na-K-ATPase
Fig. 1. Cellular mechanism of action of aldosterone and its inhi-
bition by spironolactone. The aldosterone binds to a cytoplasmic
receptor, which then attaches to the DNA in the nucleus induc-
ing RNA-controlled protein production of "aldosterone-induced
protein" (AlP). AlP is more than one protein (see text), and the
exact roles are uncertain. Postulated roles include induction of
Na-K-ATPase, induction of a cell membrane permease, and en-
hanced energy production. Spironolactone inhibits aldosterone
action by binding to an allosteric form of the aldosterone recep-
tor and inhibiting its uptake into the nucleus.
The action of aldosterone in the kidney is thought
to be through a cytoplasmic receptor followed by
nuclear uptake of the hormone receptor complex
and genomic control of production of aldosterone-
induced protein" [5]. This euphemism covers our
ignorance of the actual mechanism of the action of
aldosterone on sodium and potassium transport.
Postulates for this action include a cell membrane
permease for ionic movement, enhanced energy
production leading to increased ion transport, and
either direct or indirect effects of Na-K-ATPase,
the enzymatic equivalent of the sodium transporter
(Fig. 1). Intuitively it seems likely that Na-K-
ATPase would be this final mediator of aldosterone
action on sodium and potassium transport, although
there is little evidence to support this [3]. Studies on
the aldosterone-induced protein in toad urinary
bladder suggest both a membrane and a soluble
component, which might suggest at least two dis-
tinct actions of aldosterone [6]. In toad bladder, an-
other necessary component induced by aldosterone
is fatty acid synthesis, which is important for incor-
poration of the protein into the membrane [7]. Al-
dosterone also induces various biochemical
changes that can precede any ionic effects. The sig-
nificance of these in relation to homeostasis is un-
certain. (For review, see Refs. 3, 8, and 9.)
Reports of actions of aldosterone by nonclassical
steroid receptor systems (for example, RBC ghosts
[10] and renal Na-K-ATPase [11]), although of great
interest, are so far of doubtful significance be-
cause of the lack of adequate control studies in rela-
tion to dosage or crossreactivity by other steroids.
These effects of aldosterone on membrane-based
systems such as red cell ghosts may relate to the
binding of aldosterone to membrane preparations
[12], although this finding has not been pursued.
There is evidence to suggest that the mechanism
of action of aldosterone on different ions is, at least
in part, by different mechanisms. The sodium but
not the potassium effect is inhibited by prior treat-
ment with inhibitors of ribonucleic-acid-induced
protein synthesis [13, 14]. In turtle bladder, spi-
ronolactone acts as an inhibitor of aldosterone ef-
fect on sodium transport but as an agonist on al-
dosterone effect on hydrogen ion transport [15]. In
view of our lack of knowledge of the precise ef-
fector mechanism of aldosterone action, however,
these apparent differences are hard to interpret.
The renal responsiveness to aldosterone may be
under genetic control, at least in mice [16]. The evi-
dence for this involves separating the sodium and
the potassium responses. When the sodium and the
potassium responses were factored together as KJ
Na, however, there was no difference between the
two species of mice [16]. In all our studies on al-
dosterone in rats, the effect measured as K/Na is
reasonably constant even though the separate so-
dium and potassium effects vary widely from exper-
iment to experiment. This makes me query the sig-
nificance of observations separating the potassium
and the sodium effects.
In rats, there is some evidence of sex dependence
of the renal response to aldosterone based on dif-
fering metabolic rates [17, 18]. Again in our labora-
tory these differences were not marked.
Certainly physiologic and pharmacologic factors
can modify the renal response to aldosterone. It is
hard to demonstrate an effect of aldosterone in the
adrenalectomized rat unless it has been deprived of
potassium overnight [8]. The significance of this is
uncertain. Other factors include vena cava obstruc-
tion in the dog [19], sodium restriction in the sheep
[20], 5 days of postassium loading [21], and treat-
ment with L-dopa [22] and 5 a-dihydrocortisol [23]
in the rat. Variability in the renal response to al-
dosterone in humans may be of importance in some
cases of hypertension [24] and in the natriuresis of
fasting [25]. None of these known modifiers of the
renal response to aldosterone do so by interference
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with the aldosterone receptor, when measured in
vitro [21, 23] (Funder and Adam, unpublished).
Although there is still debate as to whether a!-
dosterone has any action in the proximal con-
voluted tubule, it seems certain that the major renal
site of action of aldosterone is the distal tubule and
the collecting ducts [8]. The action in the collecting
duct might be by direct sodium and potassium ex-
change by a luminal transporter but its action in the
distal convoluted tubule is less clear, there being
little evidence for direct sodium, potassium ex-
change [8].
The major homeostatic effect of aldosterone on
the sodium and potassium balance by the kidney
makes the renal aldosterone receptor a suitable site
for manipulation by drugs.
Aldosterone antagonists. Antagonists of aldos-
terone would be expected to promote sodium excre-
tion and potassium retention—the latter being a de-
sirable effect in view of problems of potassium loss
with most other diuretics. Aldosterone antagonists
as diuretics would be of theoretical importance in
primary or secondary hyperaldosteronism—the
secondary hyperaldosteronism either being related
to the disease state or to the reduction of extra-
cellular volume by other diuretic therapy.
(1) Spironolactone. The finding that progesterone
was natriuretic in aldosterone-treated, but not un-
treated, patients with Addison's disease [26] led to
the search for steroidal antagonists of aldosterone.
Once the antimineralocorticoid activity of spirono-
lactones was demonstrated [27], a commercial spi-
ronolactone was developed which is an effective
diuretic in primary and secondary hyperaldos-
teronism, but not in those conditions where there
are low plasma aldosterone levels [28, 29]. Under-
standing the mechanism of the action and side ef-
fects of spironolactone has been complicated by the
finding that its major metabolite, canrenone [30]
(the side chain on 7 removed) (Fig. 2), has less affin-
ity for the mineralocorticoid receptor but similar af-
finity for the testosterone receptor when compared
with spironolactone [31, 32].
So specific does the diuretic action of spironolac-
tone seem that it has been postulated as a better
marker of mineralocorticoid activity than the mea-
surement of hormone levels [33]. That is, the re-
sponse to spironolactone could be used to define in-
creased mineralocorticoid activity occurring in the
absence of raised aldosterone levels. Increased
mineralocorticoid activity with normal or low al-
dosterone levels could arise with an increased end-
organ sensitivity to aldosterone [24], or by the ac-
Aldosterorie Spironolactorie
Fig. 2. Two-dimensional representation of the structure of al-
dosterone and inhibitor spironolactone.
tion of unknown and thus unmeasurable steroids
with mineralocorticoid activity. The search for oth-
er nonclassical mineralocorticoids in an effort to ex-
plain some cases of hypertension has been and is
the subject of extensive investigations [33, 34]. Care
must be taken, however, in using spironolactone re-
sponsiveness as a measure of increased mineral-
ocorticoid activity. Hypertension due to any cause
might well respond to interruption of any aspect of
the homeostatic control of blood pressure, includ-
ing salt depletion caused by any mechanism.
The spironolactones have also proven useful in
defining the subcellular mechanism of action of al-
dosterone—particularly in demonstrating the al-
dosterone receptor. On the basis of these studies,
spironolactone is thought to act by competing for
the aldosterone receptor, which exists in two allo-
steric forms (active and inactive) and which are
readily interchangeable by the presence of agonists
or antagonists. Once bound to the receptor, the spi-
ronolactone receptor complex, unlike the aldoster-
one receptor complex, does not enter the nuclei
and thus can exert no mineralocorticoid effect
[35] (Fig. 1). Interestingly, progesterone, the sub-
stance that led to the search for spironolactone, has
also been shown to exert its antimineralocorticoid
action by a similar mechanism involving binding to
the aldosterone receptor [36].
Like many drugs, spironolactone has unwanted
side effects, including gynecomastia and impotence
in males and menstrual disturbances in females [28,
29]. The side effects are dose dependent and readily
reversible. The antiandrogenic effect involves, in
the main, both spironolactone and its metabolite,
canrenone, acting as an inhibitor of the testosterone
receptor [29, 31]. With spironolactone there is also
enhanced peripheral metabolism of androgens to es-
trogens, and inhibition of testicular biosynthesis of
CH2OH
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0
626 Adam
testosterone, These effects are, in retrospect, pre-
dictable in view of the high doses of spironolactone
and its known affinity for the testosterone receptor
[32]. Spironolactones also have other effects possi-
bly not mediated by classical steroid receptors and
of doubtful significance, for example, an inotropic
effect in the heart, proliferation of endoplasmic re-
ticulation in hepatocytes, and stimulation of hepatic
oxidizing enzyme [29].
In an attempt to avoid the unwanted side effects
of spironolactone, other drugs with similar actions
(sodium losing, potassium retaining) have been de-
veloped (for example, triamterene [28] and amilo-
ride [37]). These do not appear to act as direct al-
dosterone antagonists, however. More recently,
spironolactone analogues have been studied to see
if the affinity for the mineralocorticoid receptor can
be maintained when the affinity for the testosterone
receptor is lost. SC 25152 has CO2 CH3 substituted
for SCOCH3 in the 7 position (Fig. 2). Compared
with spironolactone, it has equivalent affinities for
the mineralocorticoid receptor but reduced affini-
ties (20%) for the testosterone receptor [38]. Recep-
tor binding, however, does not predict either ago-
nist or antagonist activity, and the electrolyte activi-
ty of SC 25152 was not studied [38]. On other
evidence, it seems likely that the 7 substitution
could induce changes in agonist to antagonist activi-
ty [31], and this drug, SC 25152, needs to be eval-
uated in this regard.
(2) /8-Deoxyaldosterone. Another, and intu-
itively more specific, approach to develop an al-
dosterone antagonist would be to modify the al-
dosterone molecule. One of the problems is that the
structural basis of mineralocorticoid activity is not
well understood. Aldosterone, 1 1-deoxycorticoster-
one, and 9-a-fluorocortisol all exhibit high binding
affinity to the mineralocorticoid receptor and are
exclusively agonist, yet their three-dimensional
structures, as determined by x-ray crystallography,
do not reveal common features to explain their spe-
cific interaction with the receptor binding site [39].
Similarly, affinity can be altered significantly by
what appear to be minor structural modifications
that are away from the apparent reactive sites (11
and 18 positions). To give some examples: (a) Add-
ing fluorine in the 9 a position to prednisolone leads
to mineralocorticoid activity, whereas adding fluo-
rine in the 6 a position does not [40]. (b) Removing
the methyl group from the 19 position enhances the
affinity of DOC for the aldosterone receptor, but the
same manipulation has variable effects on spirono-
lactone affinity for the receptor [41, 42]. All this
serves to emphasize our lack of knowledge of ste-
roidal structure-function relationships.
Notwithstanding, the above modifications of al-
dosterone have been made, and the substances
have been tested for aldosterone receptor affinity.
Any substances having receptor affinity were then
tested for agonist or antagonist activity in an al-
dosterone bioassay system. One antagonist is 18-
deoxyaldosterone, an analogue of aldosterone in
which the hemiacetal structure is replaced by a
stable 1IB, 18 oxide ring. It binds to the mineral-
ocorticoid receptor and has partial agonist (1/3) and
antagonist (2/3) activity in rat kidney bioassay and
toad bladder bioassay [43]. 18-Deoxyaldosterone
has two desirable characteristics that make side ef-
fects less likely. The first is a high affinity for the
aldosterone receptor leading to low blood level re-
quirements; the second is a negligible affinity for
androgen receptors. 18-Deoxyaldosterone may be
the basis for developing a more specific aldosterone
antagonist for clinical use.
Aldosterone agonists. Aldosterone is expensive
and needs to be given parenterally, thus limiting its
use in the treatment of hypoaldosteronism. In most
situations, hypoaldosteronism is associated with
hypoglucocorticoidism, and the administered glucu-
corticoid is selected to have some mineralocorticoid
effect (for example, cortisone acetate) that is often
adequate for sodium and potassium homeostasis.
In isolated instances of hypoaldosteronism and
in some patients with Addison's disease, an
oral analogue of aldosterone, however, would be
preferable. For this purpose, 9-a-fluorohydrocorti-
sone, a synthetic analogue of hydrocortisone, has
been proposed [44].
(1) 9- a-Fluorohydrocortisone. 9-a-Fluorohydro-
cortisone binds to both glucocorticoid and mineral-
ocorticoid receptors with high affinity [45], and as a
mineralocorticoid, it is as active on a mole-for-mole
basis as is aldosterone in the rat (Adam, unpub-
lished results) (Fig. 3). Although 9-a-fluorohydro-
cortisone appears to act as a mineralocorticoid in
man, some of its action (like hypertension in the rat
[45]) appears to be due to its glucocorticoid action.
It has been used with good effect in potassium-re-
taining or sodium-losing states and hypotension due
to hypoaldosteronism, and it may have some effect
in other potassium-retaining or sodium-losing states
(for example, renal). It is also used to produce ex-
pansion of extracellular fluid and suppression of re-
nm in diagnostic tests in patients with hypertension
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[47]. It is not certain, however, that all its effects are
produced by either a glucocorticoid or mineral-
ocorticoid mechanism.
Experimentally in sheep, 9-a-fluorohydrocorti-
sone can produce hypertension that does not de-
pend on a classical mineral or glucocorticoid mech-
anism and is also not dependent on the kidneys [48].
The site of action is unknown, but it may relate to
another experimentally induced type of hyperten-
sion—that induced by ACTH in the sheep [49]. In-
fusion of appropriate amounts of known adrenal
glucocorticoids and mineralocorticoids cannot re-
produce ACTH-induced hypertension without the
addition of either 17-OH-progesterone and/or 17-
a,20-a,di-OH progesterone [50-52]. The mecha-
nism of ACTH and 9-a-fluorohydrocortisone hyper-
tension is unknown but is of interest in regard to
drug-induced minera1ocorticoid" hypertension in
man (see below).
(2) 9-a-Fluoroprednisolone. An outbreak of hy-
pertension in Italy has been traced to nasal sprays,
taken for rhinitis [53]. These nasal sprays contain 9-
a-fluoroprednisolone, presumably included for its
glucocorticoid effects, although it is not clear
whether the manufacturer knew whether the spray
contained 9-a-fluoroprednisolone or 6-a-fluoro-
prednisolone. 9-a-Fluoroprednisolone has an affini-
ty for aldosterone receptors and an in vivo aldoster-
one-like activity equivalent to 9-a-fluorohydrocorti-
sone and aldosterone [40] (Fig. 3). There is no doubt
the nasal spray produced increased mineral-
ocorticoid activity (hypokalemic alkalosis, low
plasma renin activity, and hypertension), but the
hypertension may also have been related to some
nonmineralo, nonglucocorticoid effect similar to
that seen in the sheep with 9-a-fluorohydrocorti-
sone. In this regard, it is interesting to note that the
blood pressure returned to normal more slowly than
the hypokalemia. The extra actions of 9-a-fluoro-
hydrocortisone and 9-a-fluoroprednisolone might
explain why these substances appear to be much
better than aldosterone is in producing hyperten-
sion in sheep and man [40, 48, 54]. It should be
noted, however, that although administration of a!-
dosterone to man in the short term may produce on-
ly mild or no elevation of blood pressure [55], more
prolonged administration is far more effective [56].
(3) Liquorice extracts. Aldosterone agonist activ-
ity may also arise as an unwanted side effect of a
drug directed elsewhere. Liquorice derivatives (gly-
cyrrhetinic acid, glycyrrhizic acid, and carbenoxo-
lone as the active components) used in treatment of
peptic ulcers lead to sodium retention, hypoka-
lemia, and hypertension, all reversible by spirono-
lactone [57]. Glycyrrhetinic acid has a low but defi-
nite affinity for aldosterone receptors, which, given
the doses used, may explain its apparent mineral-
ocorticoid action [57]. Studies on the effect of car-
benoxolone on aldosterone receptors have not been
performed. The characteristics of its action and the
reversibility by spironolactone all suggest, how-
ever, that these are receptor mediated [58]. The
mode of action of glycyrrhetinic acid and carbe-
noxolone on gastric acid excretion is unknown but
may involve histamine receptor (H2) blockade. It is
of interest to note that cimetidine, a fairly specific
H2 receptor antagonist, also binds to testosterone
receptors and produces antiandrogen effects—remi-
niscent of the spironolactones [59]. Furthermore,
spironolactone inhibits the effect of carbenoxolone
on gastric acid secretion, possibly acting as an
agonist [60]. It may be there are some structural
similarities between the H2, androgen, and aldoste-
rone receptors. There is pharmacologic evidence of
Hi and H2 receptors in the kidney, but these seem
mainly vascular and no evidence has been present-
ed to show any other effect on renal function [61].
Dopamine
Dopamine is used therapeutically as an inotropic
agent and as a relatively specific renal vasodilator
[62]. Dopamine analogues are being developed, pre-
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Fig. 3. Renal response to aldosrerone (A/do) compared to 9-a-
fluorohydrocortisone (9aFF) and 9-a-fluoroprednisolone (9aFP).
The responses were not significantly different. Each point repre-
sent the mean and SEM of at least eight rats (for methods, see
Ref. 22).
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sumably in the hope of obtaining an orally active
inotropic agent or an agent to enhance renal blood
flow or GFR [63].
Therapeutic manipulation of dopaminergic sys-
tems occurs with the use of other agents with do-
paminergic activities, precursors of dopamine, do-
paminergic antagonists, and inhibitors of dopamine
synthesis (Table 1). All of these may interact with
dopaminergic systems within the kidney.
The dopaminergic renal systems may respond to
either dopamine arriving in the arterial blood or to
locally produced dopamine. It is only recently that a
radioenzymatic assay has been developed that is
specific and sensitive enough to measure plasma
dopamine levels (approximately 0.5 nmoles/liter)
[64]. The endogenous plasma levels of dopamine
are much lower than those achieved therapeutical-
ly. There is, however, some evidence for renal
binding studies (see below) that the endogenous lev-
els are appropriate for physiologic action. Addition-
al evidence that plasma dopamine may exert some
physiologic role is that the levels are modified by
sodium intake. A low sodium diet increases plasma
dopamine twofold, and there is a better correlation
between sodium intake and plasma dopamine than
there is with sodium intake and either epinephrine
or norepinephrine [65].
Dopamine is produced within the kidney as well
as elsewhere. Dopamine has been demonstrated in
renal vascular tissue by fluorescent techniques [66].
Further evidence for intrarenal production is that
the amount of dopamine excreted in the urine ex-
ceeds that which could be extracted from the
plasma [67] (Table 2). Additional evidence is the
presence of enzymes necessary for dopamine syn-
thesis—tyrosine hydroxylase and dopa decarboxy-
lase. The tyrosine hydroxylase level is dependent
on sympathetic nerve supply and is probably intra-
neuronal [68]. The dopa decarboxylase is a relative-
ly nonspecific aromatic acid decarboxylase and is
extraneuronal [68]. Dopamine production might
therefore be under neuronal or extraneuronal con-
trol, or both. The concept of tissue catecholamines
outside neuronal control is not unique, as epineph-
rifle seems to be present outside neurons in heart
[69].
The sympathetic supply to the kidney is abundant
and is directly to the tubules as well as vascular tis-
sue [68]. The actions of the sympathetic nerve sup-
ply to the kidney include, at least, direct vascular
actions and enhancement of sodium reabsorption
[70]. Other actions, however, have not been ex-
cluded and seem likely. If the dopamine production
is under neuronal control, this would enable intra-
renal release to be anatomically discrete and thus
Table 1. Drugs that may interact with dopaminergic-
mediated function in the kidney
Agonists Dopamine
L-Dopa
Bromocryptine
Antagonists Chiorpromazine
Butyrophenones
(e.g. haloperidol)
Metoclopramide
Opiates
Inhibitors of
dopamine production
outside the CNS
Carbidopa
Benzeraside
Table 2. Plasma dopamine, urinary dopamine, dopamine
clearance, and creatinine clearance in 6 normal malesa
Plasma Dopamine Dopamine Creatinine
dopamine excretion clearance clearance
nmoles/liter nmoles/hr mi/mm mi/mm
0.43 0.06 44.8 7.1 1996 453 112 7
a Values are the means SEM. The dopamine clearance ex-
ceeds creatinine clearance and estimated renal blood flow (as-
suming renal blood flow is approximately 5 times GFR) [67].
possibly have more than one action in the kidney.
This would help provide a basis for the many dif-
ferent renal actions of dopamine postulated below.
Renal actions of dopamine. The postulated renal
action of dopamine includes (1) vascular action
(dilatation; stimulation of renin release) and (2) di-
rect tubular action (sodium excretion, either in-
crease or decrease; phosphate excretion; enhance-
ment of the renal action of aldosterone).
There is ample evidence that vascular infusion of
dopamine produces renal vasodilatation [62] and a
natriuresis [62, 72, 73]. Neurogenic control of dopa-
mine-mediated renal vascular dilatation is likely to
be a physiologic control system based on the fol-
lowing evidence. Electrical stimulation of specific
areas in the midbrain and hypothalamus lead to an
increase in renal blood flow, which is blocked by
haloperidol, a dopamine receptor blocker [74].
These changes in renal blood flow can not be ex-
plained by changes in flow in other vascular beds.
More recently, there has been histofluorescent
demonstration of dopamine-containing neuronal
elements at the glomerular vascular poles [66].
These dopamine-containing structures may repre-
sent the prejunctional counterpart to the pharma-
cologically identified dopamine receptors in the re-
nal vasculature. There is also some evidence that
the rise in renin secondary to stimulation of the re-
nal sympathetic nerves is, at least in part, mediated
by dopamine [75].
The natriuresis induced by dopamine can be ex-
plained to a large extent by the renal vasodilatation.
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The question is whether a direct effect of dopamine
on the renal tubule also contributes to this natriure-
sis. The commonly cited evidence that dopamine
does have a direct tubular natriuretic effect is not
completely satisfactory. In an abstract, McGiff and
Burns [72] described a natriuretic effect of dopa-
mine even when the renal blood flow and GFR had
been reduced to below control levels by aortic con-
striction. The natriuresis, but not renal vasodilata-
tion, was blocked by phentolamine, suggesting a
possible a mediation of the sodium loss. Unfortu-
nately, complete details are not available. In dogs,
the i.v. infusion of dopamine produced a natriuresis
that occurred without any change in GFR. On the
basis of micropuncture, including tubular fluid-to-
plasma inulin ratios, the natriuresis did not occur in
the proximal tubule and, by exclusion, was attrib-
uted to the distal tubule. Renal blood flow, how-
ever, was not measured in this study [73]. More re-
cently, some preliminary evidence has been pre-
sented that shows a natriuretic effect of dopamine in
the isolated perfused rat kidney. This natriuretic ef-
fect was independent of changes of perfusion flow
rate and GFR and, by exclusion, was attributed to a
tubular effect of the dopamine [75]. There is also
indirect evidence of a natriuretic role for dopamine.
Carbidopa, an inhibitor of dopa decarboxylase and
thus dopamine production, has antinatriuretic ef-
fects, and from this a natriuretic role for dopamine
was extrapolated [77]. Further evidence that dopa-
mine may be an important natriuretic agent is based
on correlations between urine sodium and dopa-
mine excretion under varying conditions [78]. It is
important to note that in one study in rats the dopa-
mine excretion correlated with chloride intake and
not sodium intake [67], raising the possibility that
the natriuretic activity is secondary to chloruretic
activity. This needs further study.
It seems likely that the natriuretic effect is due to
dopamine produced intrarenally rather than to that
produced elsewhere. Plasma dopamine levels corre-
late inversely with sodium excretion [65], whereas
urinary dopamine excretion (presumably reflecting
intrarenal production) correlates directly with so-
dium excretion [78].
An action of dopamine to enhance sodium reab-
sorption is at variance with its proposed natriuretic
properties, but these are not mutually exclusive if
activated by anatomically discrete dopamine re-
lease, as can occur with neuronal control. Such an
antinatriuretic activity has been demonstrated for
dopamine as part of a postulated action to enhance
the renal response to aldosterone [22]. The evi-
dence for an action of dopamine on the renal action
of aldosterone has problems of interpretation. Pre-
treatment of rats with L-dopa leads to a natriuresis.
The addition of aldosterone reduces the natriuresis
and enhances potassium excretion leading to great-
er increment of K/Na than with aldosterone alone.
Other factors producing a natriuresis (sodium chlo-
ride, furosemide, theophylline) do not modify the
response to aldosterone. The enhanced response
can be blocked by haloperidol (a dopamine receptor
blocker) and carbidopa (a peripheral dopa decarbox-
ylase inhibitor). The results with carbidopa suggests
that the action of L-dopa is mediated through dopa-
mine acting outside the central nervous system [22].
The problem in interpreting these results led us to
look for a role for dopamine in aldosterone sensitiv-
ity in a more physiologic situation. Chronic potas-
sium loading produces enhanced end-organ respon-
siveness to aldosterone [21], which appears to be
mediated by dopamine as it is inhibited by both car-
bidopa and haloperidol [79].
Dopaminergic potentiation of hormonally mediated
ion transport may not be unique to the kidney. Bro-
mergocryptine, a drug with dopaminergic agonist
activity, has been demonstrated to potentiate gastrin-
mediated acid excretion in the stomach of the cat [80].
There is other indirect evidence of a role for dopa-
mine in sodium reabsorption by the kidney in that
plasma levels of dopamine rise with sodium restric-
tion [65]. These results are difficult to interpret in that
plasma levels of both norepinephrine and epinephrine
also rise. Of all these catecholamines, however, plas-
ma dopamine levels gave the best correlation with
sodium excretion [65]. Additional, very indirect,
evidence that dopamine may play a role in sodium
reabsorption is that interruption of the renal sympa-
thetic fibers leads to natriuresis and stimulation to
sodium retention [70, 81, 82]. This theory implies
that the dopaminergic control of sodium reabsorp-
tion is under neuronal control. One problem with
this interpretation is that sodium reabsorption can
also be enhanced with norepinephrine and epineph-
rine [83]. The studies done on catecholamines and
sodium reabsorption were done in the isolated per-
fused rat kidney. They did not include the infusion
of dopamine and used very high levels of proprano-
lol (10 M) as evidence of /3-receptor involvement.
They are thus incomplete and can not be interpreted
conclusively [83].
Proof of an interaction between dopamine and so-
dium reabsorption, particularly if it involves the re-
sponsiveness to aldosterone, may come with stud-
ies at a subcellular level. There is preliminary evi-
dence that dopamine interacts with Na-K-ATPase,
the enzyme equivalent of the sodium pump, and
one of the possible effector mechanisms for aldo-
sterone action [84].
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Evidence has been presented that dopamine ex-
erts some control over phosphate excretion. Both
dopamine and L-dopa, but not L-dopa with carbi-
dopa (the dopa decarboxylase inhibitor), enhanced
phosphate excretion by a mechanism independent
of parathyroid hormone or sodium excretion [85].
Whether this has a physiologic role in the control of
phosphate is not known.
Biochemical evidence suggestive of a metabolic
role for dopamine in the kidney is the enhancement
of that part of the renal metabolic rate not associat-
ed with sodium reabsorption [86] and the presence
of a dopamine-sensitive adenylate cyclase [87].
How these fit in with the physiologic roles postulat-
ed above is unclear.
The postulated actions may not be mutually ex-
clusive or antagonistic if they are anatomically dis-
crete and dopamine production is similarly discrete
and controlled by neural regulation. Circulating lev-
els of dopamine might be expected to intefere, how-
ever, with local actions unless the required concen-
trations for activation of those effector systems un-
der control from local production were higher than
those under control of plasma dopamine. The
plasma level of dopamine at renal sites of action
may be further reduced by its active clearance from
the plasma by tubular secretion [88], reducing back-
ground levels and thus facilitating discrimination of
locally released dopamine.
Dopaminergic binding studies. One way of help-
ing to define the intrarenal roles for dopamine
should be by studying the characteristics of renal
dopamine receptors. To the present, receptors have
been demonstrated pharmacologically and almost
exclusively in relation to dopaminergic control of
blood flow. In unpublished studies, we have demon-
strated binding of tritiated dopamine to homoge-
nates of kidney.
The binding characteristics of both dopamine and
haloperidol in the kidney differ markedly from those
observed in the central nervous system [91, 92].
Major differences include the lack of displacement
(and of binding itself) by apomorphine and the lack
of displacement of dopamine by d-butaclamol. The
displacement of dopamine by l-methorphan is anal-
ogous to opiate inhibition of the dopamine receptor
in the pituitary [93]. The relatively low affinity of
dopamine and haloperidol for each other's binding
sites is also of interest and suggests that each ligand
binds to a different site. In contrast to the binding of
haloperidol, dopamine binding could be inhibited by
omission of ATP or sodium, or by the addition of
potassium (20 mM) or ouabain (10-6 M) (Fig. 4).
There is growing evidence for multiple classes of
"dopamine" receptors in the central nervous sys-
tem, and the binding sites demonstrated here might
extend the number of different types [94].
Is the binding of either dopamine or haloperidol
of any physiologic significance? The opiates d- and 1-
methorphan inhibit the enhanced renal response to
aldosterone, induced by L-dopa, (Fig. 5), quite con-
sistent with their displacement of dopamine binding
in kidney homogenates. No such function for the
haloperidol sites has been defined. The effect of
opiates on dopamine binding and on the renal re-
sponse to aldosterone suggests the dopamine bind-
ing is at least pharmacologically important. (The in-
triguing possibility that this is a manifestation of an
endogenous opiate mechanism has yet to be ex-
plored. Recently, a structural similarity between
dopamine and enkephalin has been described [95].)
In addition, the effect of removing sodium or ATP
and adding potassium to the medium on dopamine
binding, but not haloperidol binding, suggests some
significance of the dopamine binding site. In this
context it is of interest to note that the binding of
catecholamines, including dopamine and /3 adre-
noreceptor agonists, but not of antagonists, is
modulated by other nucleotides, in particular GTP,
which can differentiate between agonist and antago-
nist states [96—98].
The dopamine binding requirements for sodium
or ATP and inhibition by high potassium concentra-
I100-
4
_6 75-0000
a'
50-
Co0 C
25
=
Fig. 4. Effecton 3H—dopa mine— and 3H—haloperidol-bindingof ad-
dition ofouabain (I tIM) or withdran'al of ATP (3 mM) from the
mediu,n. Both the addition of ouabain and the removal of ATP
reduce dopamine binding significantly (paired I test, P < 0.02),
but have no effect on haloperidol binding. The mean SEM of
more than five determinations are plotted.
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tion are similar to those for the enzyme Na-K-
ATPase [89]. The possible relationship between the
dopamine receptor and Na-K-ATPase is further
supported by the finding that ouabain, a specific in-
hibitor of Na-K-ATPase, inhibits dopamine bind-
ing. Such an interaction between the dopamine re-
ceptor and Na-K-ATPase may possibly explain the
observed effects of dopamine on this enzyme [84].
A similar coupling (between a receptor and an ion
transport system) has recently been proposed for
the benzodiazepine receptor and a chloride anion
channel [99].
Renal effects of dopaminergic drugs. Apart from
the difficulties in detecting renal effects of dopami-
nergic drugs owing to the kidneys ability to adapt to
specific functional loss (see introduction of section
on dopamine), any observed effects may relate to
extrarenal actions of dopamine. For instance, an ef-
fect of dopamine on sodium could be to promote
either its excretion or retention and may be mediat-
ed in the kidney directly or secondary to interaction
with aldosterone, or by an action on renin release.
Further complicating factors are that dopamine ap-
pears to inhibit angiotensin-mediated aldosterone
secretion [100, 101]. All these factors combine to
make an action of dopaminergic agents unpredict-
able, as indeed they are.
Certainly dopamine infusion is associated with a
natriuresis, largely due to its vascular effects [62].
Similarly, L-dopa, the precursor of dopamine, leads
to a natriuresis of variable extent [102]. L-Dopa may
also lead to hypotension, although this is more
likely due to a central mechanism rather than so-
dium loss [103]. Although carbidopa (the inhibitor
of dopa carboxylase) is rarely used alone, it is asso-
ciated with modest sodium retention [76]. Carbi-
dopa reduces the incidence of hypotension seen
with L-dopa treatment [104] and can be shown ex-
perimentally to block the natriuretic effect of L-
dopa [85].
Another drug with dopaminergic agonist activity,
bromocryptine, can lead to a small natriuresis,
which is unlikely to cause its hypotensive effect
[106]. The natriuresis may be directly mediated by
the kidney or be the result of the dopaminergic inhi-
bition of aldosterone release mediated by bromo-
cryptine [101, 107].
The psychotropic drug chlorpromazine is consid-
ered a classical dopaminergic receptor blocker
[108]. It acts as a diuretic, but its mechanism of ac-
tion is uncertain. Possibilities include inhibition of
ADH and inhibition of tubular reabsorption of so-
dium (possibly acting as a dopaminergic receptor
blocker). It also has nonspecific adrenergic receptor
blocking activities [109]. Haloperidol, a butyrophe-
none, is another psychotropic drug that is also used
as a dopamine receptor blocker [91]. Knowledge of
its renal action is poorly described.
Although there has been a general impression
that dopaminergic antagonists have little gross ef-
fect on renal function and that any effect might be
mediated by an extrarenal mechanism rather than
directly in the kidney, this should not stop us from
looking for small manipulations of renal function, as
even minor changes may assume importance over
the longer term. Receptor studies may help define
areas of renal function that require careful observa-
tion.
Summary
Therapeutic manipulation of renal hormone re-
ceptors is appropriate for hormone functions in
which the kidney is the most biologically significant
end organ. Renal hormone receptors may also be
affected by drugs directed elsewhere. Two kidney
hormone receptor systems have been discussed—
those for aldosterone and for dopamine.
Aldosterone agonists (9-cE-fluorohydrocortisone)
and antagonists (spironolactone) are used to manip-
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Fig. 5. Effect of L-dopa and d- and 1-methorphan on the renal
response to aldosterone. The renal response is defined as (K2![K1
+ K2]) ÷ (Na2/[Na1 + Na2]), and each point represents the mean
and 5EM of at least eight rats (for methods, see Ref. 22). Pre-
treatment by L-dopa (100 mg/kg) leads to an enhanced response
to aldosterone mediated by dopaminergic mechanisms [22] (see
text). Both I, and to a lesser extent d-methorphan (1 mg/kg), giv-
en prior to the basal urine, inhibited the dopaminergic enhance-
ment of the renal response to aldosterone (10 pg/kg). This inhibi-
tion was significant (P <0.02) with l-methorphan.
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ulate sodium and potassium balance. Unintentional
manipulation of the aldosterone receptor causing
sodium retention and hypertension can occur with
putative glucocorticoids (9-a-fluoroprednisolone)
administered in nasal sprays as well as with liquo-
rice extracts used to treat peptic ulcers.
Dopamine agonists can increase renal blood flow
but may also interact (as may antagonists) with non-
vascular renal dopamine receptors. In studies on
pig kidney, microsomal fractions 3H-dopamine and
8H-haloperidol can be demonstrated to bind specifi-
cally, probably to two distinct sites. Both 3H-dopa-
mine binding and dopamine-mediated enhancement
of the renal response to aldosterone were inhibited
by opiates (methorphan). This suggests a direct
tubular action of dopamine on aldosterone-mediated
potassium and sodium transport.
Other postulated nonvascular dopaminergic ef-
fects include inhibition of proximal tubular sodium
reabsorption and enhancement of phosphate excre-
tion.
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